Expression of human clotting factor Ⅸ mediated by recom- binant lentiviral vector in cultured cells and hemophilia B mice

Hemophilia B, a serious bleeding disorder, is an inherited X chromosome-linked disease for the deficiency or inactivity of human clotting factor Ⅸ (hFⅨ). Though factor substitution therapy has greatly improved the lives of hemophiliac patients, there are still limitations to the current treatment, which have triggered interest in alternative treatments by gene therapy[1]. Based on preclinical studies in rabbits[2], our lab had first initiated an ex vivo gene therapy clinical trial whereby a…     

Expression of biologically active human clotting factor Ⅸ(hFⅨ) in the mammary gland of transgenic mice

The DNA of human factor Ⅸ (hFⅨ) gene vector pMCⅨm, which had been proven to be able to express in in vitro and living cells, was introduced into 586 zygotes of Kunming White Mice by positive pressure microinjection technique with manual operation. The 499 survival embryos after microinjection were then transferred into pseudopregnant recipient mice and 216 F 0 pups were born. The analysis of PCR and Southern blot hybridization showed that, of the 216, 6 (2 females and 4 males) were integrated with foreign DNA in their genomes, giving an integration frequency of 3% (6/216). Two F\-0 female transgenic mice could express hFⅨ protein in their milk and the content was over 100 ng/mL as measured with ELISA. The biological activities of hFⅨ in the milk of two F\-0 mice were 44 67% and 79 43%, respectively.     

Polycistronic strategy for cyanobacterial expression vector construction: Co-transcription of a human gene and a selective marker gene

A polycistronic expression vector, pKGA-NTF1, was constructed for the cyanobacterium. Within this vector, the spectinomycin/streptomycin resistance gene (aadA) facilitated the selection of transformants when co-transcribed with favorite genes. A natural glnA gene was selected as the platform to introduce the plasmid into a neutral site of the Synechococcus sp. PCC 7002 chromosome. Function of the vector was demonstrated by the insertion of a modified human Trefoil factor 3 gene (NTF1) to upstream of the aadA gene and by the analyses of the transformed strains. Antibiotics resistance assays showed that the dicistronic expression cassette conferred high spectinomycin resistance to both the E. coli cells and the Synechococcus cells. PCR analysis and Western-blot analysis were carried out to confirm the integration and expression of the NTF1 gene, respectively. Through simple molecular manipulations, the artificial polycistronic structure described here can be conveniently used to express other favorable genes or operons in cyanobacteria, and to study the cyanobacterial gene expression as well.     

Efficient expression of human factor Ⅸ cDNA in liver mediated by hydrodynamics-based plasmid administration

The transfection of plasmid DNA into mammalian cells is an indispensable tool in the study of gene transfer and gene function. Since the original report in 1990 on the successful expression of a reporter gene in muscle[1], plasmid DNA injection has been widely used to mediate gene transfer study. As a gene transfer vector, naked DNA has many obvious advantages. It is easy and cheap to be prepared and more safe after transfection. But the plasmid mediated gene expression is low because of t…     

重组腺相关病毒的小量制备与体内体外感染研究

 重组腺相关病毒(rAAV)是近年来发展的较为成熟的一种病毒基因载体, 常用于过表达或者敲低等动物模型的建立与基因治疗等。本研究使用三质粒共转染的方法, 在HEK293细胞中包装出含绿色荧光蛋白(EGFP)基因的rAAV, 通过一系列实验, 确定纯化方法为脱氧胆酸钠裂解, 高浓度NaCl去除杂蛋白, 最后通过肝素层析柱纯化, 经超滤管浓缩后其滴度可达10¹³ gene copys/mL以上。将纯化后的rAAV 感染HEK293 细胞, 通过实验确定使用感染复数为10⁶、感染3 d 的细胞能够表达出高水平的EGFP。将rAAV注射入大鼠中脑黑质致密部, 经过3周的感染发现, rAAV可以特异性地感染多巴胺能神经元, 表达出EGFP。通过以上实验, 建立了一个在实验室小量制备rAAV的方法, 且此方法制备的rAAV完全满足体内与体外实验的要求。     

Expression of human clotting factor Ⅸ mediated by recom- binant lentiviral vector in cultured cells and hemophilia B mice

To explore the expression of human clotting factor Ⅸ (hFⅨ) cDNA in vitro and the feasibility of gene therapy for hemophilia B mice mediated by recombinant lentiviral vector, a recombinant hFⅨ lentiviral vector driven by ubiquitin-C promoter, FUXW, and by ABP liver specific promoter, FAXW, was constructed respectively. Recombinant lentivirus was harvested from 293T cells by calcium phosphate-mediated transient cotransfection of three plasmids (transgene vector, CMV腞8.2, VSV-G). hFⅨ expression was detected in supernatant of 293T, BHK and L-02 cells infected with FUXW virus, whereas higher expression of hFⅨ levels (630 ng/106 cells/48 h) was detected only in L-02 cells infected with FAXW virus. Serum hFⅨ antigen was detected in all hemophilia B mice treated with FAXW virus by tail vein injection, an efficiency level of hFⅨ was observed (45 ng/mL, approximately 1% of normal human levels), the expression lasted for more than 60 d. The results indicated that HIV-based lentiviral vectors offer a promising approach to the gene therapy of hemophilia B.     

Preparation of rAAV/hFⅨ by HSV/AAV hybrid helper virusand evaluation of its safety

Hemophilia B is a hemorrhagic disease resulting from Factor Ⅸ gene (hFⅨ) mutation as an X-linked recessive inherited trait. The incidence of this disease is 1 in 30000. Clinical treatments depend mainly upon blood transfusions or administration of prothrombin complex so that patients are at the risk of infections with the HIV and hepatitis viruses. Gene therapy offers an attractive alternative in the treatment of hemophilia B by eliminating those risks. In 1991, our lab conducted clinica…     

Therapeutic induction of angiogenesis by direct myocardial administration of an adenovirus vector encoding human hepatocyte growth factor gene and its safety

After the study in vitro and in rats, we assessed further the effects and safety of local angiogen therapy using intramyocardial delivery of an adenovirus carrying hepatocyte growth factor gene (Ad-HGF) in a canine ischemia model. The angiogenic activity of Ad-HGF was evaluated from three aspects. First, the augmentation of collateral vessel development was assessed by angiography 30 d after surgery. The results showed that the density of collateral vessels in treated group was higher than that of control group. Secondly, infarct size was evaluated by TTC staining and image analysis. The results showed that the infarct size of treated group was smaller than that of control group. Thirdly, the myocardial regional blood flow was determined by the method of colored microspheres. The results showed that the blood flow recovered to the level before ligation in treated group, but that of the control group was lower than normal level. In addition, during the study of chronic toxicity, we tested the anti-adenovirus antibodies by neutralization method. The antibodies yielded after the fourth injection decreased slowly from peak level and disappeared 12 weeks after drug withdrawal. Overall, Ad-HGF can promote angiogenesis in ischemic myocardium and reduce infarct size. So this method may be considered as a therapeutic angiogenesis induction strategy for ischemic disease including myocardial infarction and peripheral artery disease. At the same time, Ad-HGF could induce the yield of anti-adenovirus antibodies to neutralize adenovirus, which may be the mechanism of adenovirus clearance.     

重组人粒细胞集落刺激因子的摇瓶发酵研究

目的 优化重组大肠杆菌生产人粒细胞集落刺激因子摇瓶发酵工艺条件。方法 利用摇瓶系统地考查rhG-CSF茵株培养温度、诱导时机、pH值、溶氧、种子茵龄、接种量等工艺条件，选择出最佳的摇瓶培养条件。结果 最佳条件为：培养温度30℃；初始pH值在7．0～7．2；装液量20％；摇床转速180r／min；种子菌龄在A600为1．0～1．5时接种，并在对数生长前期(A600=1．0)时诱导4h。在此优化的培养条件下，在摇瓶中使用优化后的M9培养基时，rhG-CSF的表达量占茵体总蛋白的36．5％，光密度达5．85。结论 构建的rhG-CSF工程菌发酵的稳定性和重复性良好，可作为rhp-CSF的大规模生产提供可靠的放大依据。     

GFP标记的GDNF重组腺病毒载体的构建和体内外表达

通过构建绿色荧光蛋白(GFP)和胶质细胞源性神经营养因子(GDNF)共表达的腺病毒载体,讨论其在治疗脊髓和脑有关神经系统疾病的潜在应用价值,了解腺病毒载体在大鼠体内的分布及在体外分泌外源基因产物能力,并对其生物安全性作了初步考察,为GDNF重组腺病毒载体在临床和基础研究中的应用作了一定准备．     

Adeno-associated virus-mediated integration and expression of human P-globin gene with the core fragment of locus control region in erythroid cells

To improve the integration stability and expression of the transferred human p-globin gene, the two recombinant adeno-associated virus (AAV) vectors containing the human [3-globin gene with a single or multiple DNase I hypersensitive site (HS) core fragment of the LCR were constructed. These recombinants were respectively introduced into MEL cells via AAV-mediated gene transfer to investigate their integration and expression. The results suggested that following AAV vector-mediated gene transfer, the human [3-globin gene with the multiple HS core fragment of the LCR could steadily integrate into MEL cells and confer an expression level comparable with endogenous mouse a-globin gene.